Sunday, June 12
6:45–7:45 am PDT
Cerianna: Seeing Deeper into Recurrent or Metastatic Breast Cancer
Sponsored by GE Healthcare
Speaker: Gary Ulaner, MD, PhD, FACNM, James & Pamela Muzzy Endowed Chair of Molecular Imaging & Therapy, Hoag Family Cancer Institute
- Understand the concept of estrogen receptor (ER) discordance
- Realize the unique mechanism of action of Cerianna PET/CT
- Recognize how detecting whole-body ER+ lesions may better inform clinical decisions
- Learn about the clinical applications for Cerianna use
Important Safety Information for Cerianna™ (fluoroestradiol F 18) Injection
INDICATIONS AND USAGE: CERIANNA is indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer.
Limitations of Use: Tissue biopsy should be used to confirm recurrence of breast cancer and to verify ER status by pathology. CERIANNA is not useful for imaging other receptors, such as human epidermal growth factor receptor 2 (HER2) and the progesterone receptor (PR).
ADVERSE REACTIONS: In Clinical Trials (n=1207) the most common adverse reactions seen occurred at a rate < 1%: were injection-site pain and dysgeusia. To report SUSPECTED ADVERSE REACTIONS, contact Zionexa US Corp, a GE Healthcare Company, at +1-800-654-0118 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For full Prescribing Information click here.
6:45–7:45 am PDT
An early look at immune responses - How can zirconium 89-Df crefmirlimab advance our understanding?
Sponsored by ImaginAb
Moderator: Ian Wilson, CEO, ImaginAb
Presenters: Mike Farwell, MD, Assistant Professor, University of Pennsylvania; Kim Margolin, MD, FASCO, Medical Director, Melanoma Program, St. John’s Cancer Institute; Kevin Maresca, Pfizer, Head of PET and Molecular Imaging
Panel Members: Professor Andrew Scott, Director, Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia and Anna Wu, Co-Founder and Chief Scientific Advisor, ImaginAb
During the session, we will lead you through the development path and potential benefits of our investigational agent zirconium 89-Df crefmirlimab and how it could help in gaining a clearer insight into CD8 + cell distribution and responses. We will present and discuss current clinical data and also provide details of our currently recruiting Phase IIb ‘iPREDICT’ trial that aims to assess the ‘predictive’ performance of zirconium 89-Df crefmirlimab in measuring clinical responses in patients. In addition, Pfizer (one of our consortium members) will present pre-clinical study data and outline how they design clinical trials using CD8 imaging.
11:15 am–12:15 pm PDT
18F-rhPSMA-7.3, a unique investigational prostate-specific membrane antigen (PSMA)-targeted PET imaging agent for men with prostate cancer.
Sponsored by Blue Earth Diagnostics
- Andrei S. Purysko, MD, Cleveland Clinic, Imaging Institute
- David Gauden, D.Phil., CEO, Blue Earth Diagnostics, Ltd.
- Eugene Teoh, MBBS, MRCP, FRCR, D.Phil., CMO, Blue Earth Diagnostics Ltd.
In this session an overview of the investigational agent 18F-rhPSMA-7.3 will be provided. The content will include an overview of the rhPSMA technology and mechanism of action, Clinical Data on Biodistribution of 18F-rhPSMA-7.3 from a Phase 1 Trial, data from a retrospective analysis on 18F-rhPSMA-7.3 in Patients with Primary Prostate Cancer and in Patients with Recurrent Prostate Cancer. In addition to this a summary of the Phase 3 SPOTLIGHT Trial will be provided.
This program is sponsored by Blue Earth Diagnostics. No CE credits will be provided.
11:15 am–12:15 pm PDT
Case Review Series
Sponsored by Lantheus
Speakers: Andrei Iagaru, MD, Professor of Radiology - Nuclear Medicine, Stanford University, Stanford, CA and Steven Rowe, MD, PhD, Associate Professor of Radiology & Radiological Science, Johns Hopkins University, Baltimore, MD
In this session the panel will highlight patient cases with the following objective: Identify the role of PSMA PET/CT as a component of best practices for identifying suspected metastasis or disease recurrence in men with prostate cancer.
6:30–7:30 pm PDT
Translational Cancer Imaging Research in the Era of Precision Medicine
Sponsored by United Imaging
- Dr. Jeffrey Yap, PhD, Research Professor in the Department of Radiology and Imaging Sciences at the University of Utah, Director of the Center for Quantitative Cancer Imaging, Member of the Experimental Therapeutics Program at the Huntsman Cancer Institute
- Chuan Huang, PhD, Assistant Professor of Radiology, Psychiatry; Director, PET/MR Clinical Research, Stony Brook University
6:30–8:30 pm PDT
FAP Ligands for Imaging and Therapy
FAP (fibroblast activation protein) as a diagnostic and therapeutic target for radiopharmaceuticals has seen many advances in recent years. This special session will bring together researchers and industry sponsors to discuss the latest progress in this space.
Click here for SOFIE FAPI Flyer.
Professor Ken Herrmann, MD, MBA, University Hospital Essen
Professor Johannes Czernin, MD, University of California, Los Angeles
Professor Frederik L. Giesel, MD, MBA, University Hospital Düsseldorf, Germany
Associate Professor Jeremie Calais, MD, MSc, University of California, Los Angeles
Professor Thomas Hope, MD, University of California, San Francisco
Robin Hallett, PhD, VP Discovery and Translational Sciences, POINT Biopharma
Sherly Mosessian, PhD, Chief Scientific Officer, SOFIE Biosciences
Elcin Zan, MD, Director, Nuclear Theranostics, New York University
Curt Wolfgang, PhD, VP, Clinical Development, Clovis Oncology